Metagenomi Therapeutics, Inc. (MGX) shareholders
Close on Nov 17, 2026Market cap $23.84MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bayer HealthCare LLC Joint filing with Bayer US Holding LP (10.80%), Bayer World Investments B.V. (10.80%) and 1 more | 4,050,997 | 10.80% | 13G (passive) | Sep 30, 2024 |
| Thomas Brian C. | 2,762,142 | 7.30% | 13G (passive) | Jun 30, 2026 |
| Koichiro Nakamura Joint filing with Phillip Wickham (5.10%) | 1,892,873 | 5.10% | 13G (passive) | Feb 9, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,077,700 | 2.85% | $1.28M | +19,756 | 0.00% |
| Renaissance Technologies LLC | 742,400 | 1.97% | $883.46K | −45,500 | 0.00% |
| Catalio Capital Management, LP | 528,993 | 1.40% | $629.50K | – | 0.12% |
| Peapod Lane Capital LLC | 525,024 | 1.39% | $624.78K | +8,263 | 0.42% |
| Two Sigma Investments, LP | 513,701 | 1.36% | $611.30K | +16,934 | 0.00% |
| Bridgeway Capital Management, LLC | 400,300 | 1.06% | $476.36K | +4,500 | 0.01% |
| Wells Fargo & Company/Mn | 379,508 | 1.00% | $451.61K | +177,370 | 0.00% |
| Geode Capital Management, LLC | 288,665 | 0.76% | $343.67K | −69,535 | 0.00% |
| Pura Vida Investments, LLC | 264,391 | 0.70% | $314.63K | – | 1.91% |
| BlackRock, Inc. | 257,631 | 0.68% | $306.58K | +27,497 | 0.00% |
| Vanguard Fiduciary Trust Co | 171,251 | 0.45% | $203.79K | +1,077 | 0.00% |
| Jacobs Levy Equity Management, Inc | 160,000 | 0.42% | $190.40K | −222,153 | 0.00% |
| State Street Corp | 119,850 | 0.32% | $142.62K | −577 | 0.00% |
| Millennium Management LLC | 114,025 | 0.30% | $135.69K | −56,079 | 0.00% |
| Man Group plc | 109,130 | 0.29% | $129.87K | +30,494 | 0.00% |
| Resolute Advisors LLC | 89,944 | 0.24% | $107.03K | – | 0.03% |
| Marquette Asset Management, LLC | 72,121 | 0.19% | $85.82K | New | 0.01% |
| Northern Trust Corp | 68,938 | 0.18% | $82.04K | −6,234 | 0.00% |
| RBF Capital, LLC | 64,021 | 0.17% | $76.19K | – | 0.00% |
| XTX Topco Ltd | 55,707 | 0.15% | $66.29K | +15,125 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 43 | 6M | 16.6% | 4 / 12 | 13 / 8 | 0M | 1M |
| Q1 2026 | 48 | 6M | 17.1% | 5 / 9 | 16 / 12 | 2M | 1M |
| Q4 2025 | 56 | 7M | 18.1% | 11 / 14 | 17 / 9 | 2M | 1M |
| Q3 2025 | 58 | 6M | 16.0% | 9 / 12 | 22 / 19 | 1M | 2M |
| Q2 2025 | 69 | 8M | 20.4% | 16 / 20 | 20 / 26 | 2M | 4M |
| Q1 2025 | 79 | 10M | 25.9% | 11 / 28 | 20 / 8 | 1M | 2M |
| Q4 2024 | 77 | 11M | 28.5% | 23 / 30 | 13 / 13 | 6M | 7M |
| Q3 2024 | 67 | 12M | 30.9% | 23 / 21 | 10 / 9 | 2M | 2M |
| Q2 2024 | 54 | 12M | 32.3% | 15 / 15 | 14 / 11 | 1M | 2M |
| Q1 2024 | 50 | 13M | 35.4% | 50 / 0 | 0 / 0 | 13M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
13 funds held MGX in Q2 2026, 62% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 741,407 | 1.96% | $882.27K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 327,100 | 0.87% | $389.25K | 0.39% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 315,460 | 0.84% | $375.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 189,092 | 0.50% | $257.17K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 95,479 | 0.25% | $113.62K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 62,200 | 0.16% | $74.02K | 0.05% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 47,211 | 0.12% | $64.21K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 36,088 | 0.10% | $49.08K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 21,951 | 0.06% | $29.85K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 20,833 | 0.06% | $24.79K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 6,882 | 0.02% | $8.19K | 0.00% | Jun 30, 2026 |
| Spectrum Fund | 5,496 | 0.01% | $6.54K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 2,600 | 0.01% | $3.09K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jian Irish | See Remarks, Director | 668,107 | 1.77% | Sep 10, 2026 |
| Matthew Wein | See Remarks | 126,133 | 0.33% | Sep 10, 2026 |
| Pamela Wapnick | Chief Financial Officer | 206,580 | 0.55% | Sep 10, 2026 |
| Sarah B. Noonberg | Chief Medical Officer | 109,135 | 0.29% | Jun 9, 2025 |
| Laurence Reid | Director | 20,000 | 0.05% | Sep 11, 2026 |
| Eric Bjerkholt | Director | – | – | Jun 11, 2026 |
| Willard H. Dere | Director | 51,275 | 0.14% | Jun 11, 2026 |
| Juergen Eckhardt | Director | – | – | Jun 11, 2026 |
| Brian C. Thomas | Director | 2,510,960 | 6.65% | Dec 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Laurence Reid Director | Sep 9, 2026 | Buy | +117 | $1.18 | $138 | 20,000 |
| Laurence Reid Director | Sep 9, 2026 | Buy | +19,883 | $1.17 | $23.26K | 19,883 |
| Pamela Wapnick Chief Financial Officer | Sep 8, 2026 | Sale | −1,911 | $1.16 | $2.22K | 206,580 |
| Matthew Wein See Remarks | Sep 8, 2026 | Sale | −358 | $1.16 | $415 | 126,133 |
| Jian Irish See Remarks, Director | Sep 8, 2026 | Sale | −2,140 | $1.16 | $2.48K | 375,393 |
| Matthew Wein See Remarks | Jun 5, 2026 | Sale | −558 | $1.30 | $725 | 126,491 |
| Pamela Wapnick Chief Financial Officer | Jun 5, 2026 | Sale | −2,884 | $1.30 | $3.75K | 208,491 |
| Jian Irish See Remarks, Director | Jun 5, 2026 | Sale | −3,737 | $1.30 | $4.86K | 377,533 |
| Matthew Wein See Remarks | Apr 1, 2026 | Award | +11,000 | – | – | 125,549 |
| Jian Irish See Remarks, Director | Apr 1, 2026 | Award | +46,000 | – | – | 379,770 |
| Pamela Wapnick Chief Financial Officer | Apr 1, 2026 | Award | +24,000 | – | – | 211,375 |
| Matthew Wein See Remarks | Mar 5, 2026 | Sale | −482 | $1.60 | $771 | 114,549 |
| Pamela Wapnick Chief Financial Officer | Mar 5, 2026 | Sale | −1,581 | $1.60 | $2.53K | 187,375 |
| Jian Irish Chief Executive Officer, Director | Mar 5, 2026 | Sale | −1,607 | $1.60 | $2.57K | 333,770 |
| Jian Irish Chief Executive Officer, Director | Dec 5, 2025 | Gift | −228,462 | – | – | 335,377 |
| Brian C. Thomas Director | Dec 5, 2025 | Sale | −3,830 | $1.77 | $6.78K | 2,510,960 |
| Pamela Wapnick Chief Financial Officer | Dec 5, 2025 | Sale | −1,576 | $1.77 | $2.79K | 188,956 |
| Jian Irish Chief Executive Officer, Director | Dec 5, 2025 | Sale | −1,602 | $1.77 | $2.84K | 563,839 |
| Matthew Wein See Remarks | Dec 5, 2025 | Sale | −199 | $1.77 | $352 | 115,031 |
| Jian Irish Chief Executive Officer, Director | Dec 1, 2025 | Award | +211,000 | $1.60 | $337.60K | 565,441 |
| Jian Irish Chief Executive Officer, Director | Dec 1, 2025 | Award | +37,500 | $1.60 | $60.00K | 354,441 |
| Pamela Wapnick Chief Financial Officer | Dec 1, 2025 | Award | +120,000 | $1.60 | $192.00K | 190,532 |
| Matthew Wein See Remarks | Dec 1, 2025 | Award | +96,000 | $1.60 | $153.60K | 115,230 |
| Brian C. Thomas Director | Sep 5, 2025 | Sale | −2,701 | $1.81 | $4.89K | 2,514,790 |
| Jian Irish Chief Executive Officer, Director | Sep 5, 2025 | Sale | −1,602 | $1.81 | $2.90K | 316,941 |
| Pamela Wapnick Chief Financial Officer | Sep 5, 2025 | Sale | −1,576 | $1.81 | $2.85K | 70,532 |
| Matthew Wein See Remarks | Sep 5, 2025 | Sale | −199 | $1.81 | $360 | 19,230 |
| Brian C. Thomas Chief Executive Officer, Director | Jun 6, 2025 | Sale | −10,785 | $1.75 | $18.87K | 2,517,491 |
| Pamela Wapnick Chief Financial Officer | Jun 6, 2025 | Sale | −1,576 | $1.75 | $2.76K | 72,108 |
| Jian Irish See Remarks, Director | Jun 6, 2025 | Sale | −6,390 | $1.75 | $11.18K | 315,543 |
| Matthew Wein See Remarks | Jun 6, 2025 | Sale | −199 | $1.75 | $348 | 16,693 |
| Sarah B. Noonberg Chief Medical Officer | Jun 6, 2025 | Sale | −5,239 | $1.75 | $9.17K | 109,135 |
| Pamela Wapnick Chief Financial Officer | Apr 1, 2025 | Award | +14,000 | – | – | 73,684 |
| Sarah B. Noonberg Chief Medical Officer | Apr 1, 2025 | Award | +14,000 | – | – | 114,374 |
| Brian C. Thomas Chief Executive Officer, Director | Apr 1, 2025 | Award | +32,000 | – | – | 2,528,276 |
| Matthew Wein See Remarks | Apr 1, 2025 | Award | +3,650 | – | – | 13,117 |
| Matthew Wein See Remarks | Apr 1, 2025 | Award | +3,775 | – | – | 16,892 |
| Jian Irish See Remarks, Director | Apr 1, 2025 | Award | +23,000 | – | – | 321,933 |
| Pamela Wapnick Chief Financial Officer | Mar 5, 2025 | Sale | −1,808 | $1.87 | $3.38K | 59,684 |
| Matthew Wein See Remarks | Mar 5, 2025 | Sale | −930 | $1.87 | $1.74K | 9,467 |
| Pamela Wapnick Chief Financial Officer | Dec 5, 2024 | Sale | −1,559 | $1.86 | $2.90K | 61,492 |
| Pamela Wapnick Chief Financial Officer | Sep 5, 2024 | Sale | −6,265 | $2.88 | $18.04K | 63,051 |
| Matthew Wein See Remarks | Apr 1, 2024 | Award | +10,397 | – | – | 10,397 |
| Simon Harnest See Remarks | Apr 1, 2024 | Award | +11,552 | – | – | 122,664 |
| Brian C. Thomas Chief Executive Officer, Director | Apr 1, 2024 | Award | +118,992 | – | – | 2,496,276 |
| Luis Borges Chief Scientific Officer | Apr 1, 2024 | Award | +69,316 | – | – | 69,316 |
| Simren Delaney See Remarks | Apr 1, 2024 | Award | +6,931 | – | – | 93,892 |
| Jian Irish See Remarks, Director | Apr 1, 2024 | Award | +70,471 | – | – | 298,933 |
| Sarah B. Noonberg Chief Medical Officer | Apr 1, 2024 | Award | +57,763 | – | – | 100,374 |
| Pamela Wapnick Chief Financial Officer | Apr 1, 2024 | Award | +69,316 | – | – | 69,316 |
| Holdings A/S Novo 10% owner | Feb 13, 2024 | Conversion | +839,175 | – | – | 939,175 |
| Holdings A/S Novo 10% owner | Feb 13, 2024 | Buy | +800,000 | $15.00 | $12.00M | 1,739,175 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +509,855 | – | – | 4,050,997 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +1,770,888 | – | – | 1,770,888 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +1,180,592 | – | – | 2,951,480 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +589,662 | – | – | 3,541,142 |
| Sebastian Bernales Director | Feb 13, 2024 | Conversion | +1,896,445 | – | – | 1,896,445 |
| Sebastian Bernales Director | Feb 13, 2024 | Conversion | +513,004 | – | – | 769,845 |
| Holdings A/S Novo 10% owner | Feb 9, 2024 | Buy | +100,000 | $10.25 | $1.03M | 100,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Metagenomi Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,151 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sarah B. Noonberg FORMER OFFICER | Sep 11, 2025 | 35,832 | $68.08K | Sep 11, 2025 | STOCK AWARD |
| Sebastian Bernales Affiliate | Jul 9, 2025 | 769,845 | $1.47M | Jul 9, 2025 | Conversion of Common Units |
See a number that looks wrong?